Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (71)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Homburg, R.
Right arrow Articles by Jacobs, H.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homburg, R.
Right arrow Articles by Jacobs, H.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 5, No. 1, pp. 32-35, 1990
© 1990 European Society of Human Reproduction and Embryology

research-article

Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries

R. Homburg1, A. Eshel, J. Kilborn, J. Adams and H.S. Jacobs

Cobbold Laboratories, The Middlesex Hospital London WIN 8AA, UK

Correspondence: 1To whom correspondence should be addressed

This study was designed to compare the results of treatment with, firstly, exogenous gonadotrophins, with (57 cycles) and without (65 cycles) pretreatment with a superactive analogue of luteinizing hormone releasing hormone (LHRH) and, secondly, pure follicle stimulating hormone (FSH) (50 cycles) with those of human menopausal gonadotrophin (HMG) (72 cycles) in 46 women with clomiphene-citrate-resistant anovulation associated with polycystic ovaries. Patients randomly allocated to the analogue group received buserelin (Suprefact, Hoechst, UK, Ltd, Hounslow, Middlesex), 800 /µg/day by nasal insufflation and when hypogonadism was achieved, patients were again randomly allocated for ovarian stimulation with either FSH or HMG. Controls received FSH or HMG alone. Patients pretreated with the analogue had similar pregnancy and ovulation rates, needed larger doses and more days of gonadotrophin therapy and had more ovarian overstimulation than those receiving no pretreatment. The role of superactive LHRH analogues for induction of a single ovulation for in-vivo fertilization is thus uncertain. Pure FSH had no advantages over HMG, the LH content of HMG having no deleterious effect on the ovary.

Key words: gonadotrophins/infertility/LHRH analogue/PCO


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Consensus on infertility treatment related to polycystic ovary syndrome
Hum. Reprod., March 1, 2008; 23(3): 462 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Dias, R. McNamee, and A. Vail
Evidence of improving quality of reporting of randomized controlled trials in subfertility
Hum. Reprod., October 1, 2006; 21(10): 2617 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. E. Messinis
Ovulation induction: a mini review
Hum. Reprod., October 1, 2005; 20(10): 2688 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. H. Balen, C. J. Hayden, and A. J. Rutherford
Clinical efficacy of recombinant gonadotrophins
Hum. Reprod., June 1, 1999; 14(6): 1411 - 1417.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.